117 related articles for article (PubMed ID: 37840516)
1. CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan.
Muley T; Schneider MA; Meister M; Thomas M; Heußel CP; Kriegsmann M; Holdenrieder S; Wehnl B; Rolny V; Mang A; Gerber R; Herth F
Tumour Biol; 2024; 46(s1):S163-S175. PubMed ID: 37840516
[TBL] [Abstract][Full Text] [Related]
2. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
[TBL] [Abstract][Full Text] [Related]
3. Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150.
Mang A; Zou W; Rolny V; Reck M; Cigoianu D; Schulze K; Holdenrieder S; Socinski MA; Shames DS; Wehnl B; Patil NS
Tumour Biol; 2024; 46(s1):S177-S190. PubMed ID: 37545290
[TBL] [Abstract][Full Text] [Related]
4. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
[TBL] [Abstract][Full Text] [Related]
5. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
Front Immunol; 2020; 11():1173. PubMed ID: 32587591
[No Abstract] [Full Text] [Related]
6. Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study.
Lang D; Haslinger W; Akbari K; Scala M; Hergan B; Asel C; Horner A; Wass R; Brehm E; Kaiser B; Lamprecht B
Lung Cancer (Auckl); 2020; 11():113-121. PubMed ID: 33376433
[TBL] [Abstract][Full Text] [Related]
7. Dynamic monitoring of serum tumor markers as prognostic factors in patients with advanced non-small-cell lung cancer treated with first-line immunotherapy: a multicenter retrospective study.
Yang X; Xiao Y; Zhou Y; Deng H; Yuan Z; Dong L; Lan J; Hu H; Huang J; Huang S
Ther Adv Med Oncol; 2023; 15():17588359231206282. PubMed ID: 37920256
[TBL] [Abstract][Full Text] [Related]
8. CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors.
Dall'Olio FG; Abbati F; Facchinetti F; Massucci M; Melotti B; Squadrilli A; Buti S; Formica F; Tiseo M; Ardizzoni A
Ther Adv Med Oncol; 2020; 12():1758835920952994. PubMed ID: 33193825
[TBL] [Abstract][Full Text] [Related]
9. Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer.
He L; Teng Y; Jin B; Zhao M; Yu P; Hu X; Zhang J; Li S; Gao Y; Liu Y
BMC Cancer; 2010 Dec; 10():681. PubMed ID: 21156055
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
11. Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer.
Yoshimura A; Uchino J; Hasegawa K; Tsuji T; Shiotsu S; Yuba T; Takumi C; Yamada T; Takayama K; Hiraoka N
Transl Lung Cancer Res; 2019 Jun; 8(3):227-234. PubMed ID: 31367536
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.
Jung M; Kim SH; Lee YJ; Hong S; Kang YA; Kim SK; Chang J; Rha SY; Kim JH; Kim DJ; Cho BC
Exp Ther Med; 2011 Jul; 2(4):685-693. PubMed ID: 22977560
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study.
Li X; Lu D; Zhang Z; Zhang Y; Wang J; Hu Y
J Thorac Dis; 2022 Oct; 14(10):4125-4135. PubMed ID: 36389301
[TBL] [Abstract][Full Text] [Related]
15. Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations.
Dong J; Tong S; Shi X; Wang C; Xiao X; Ji W; Sun Y
Cancer Manag Res; 2020; 12():13607-13616. PubMed ID: 33447080
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008-2022 update.
Trulson I; Holdenrieder S
Tumour Biol; 2024; 46(s1):S111-S161. PubMed ID: 37927288
[TBL] [Abstract][Full Text] [Related]
17. Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients With Advanced Non-Small Cell Lung Cancer.
Minami S; Ihara S; Tanaka T; Komuta K
World J Oncol; 2020 Feb; 11(1):9-22. PubMed ID: 32095185
[TBL] [Abstract][Full Text] [Related]
18. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
[TBL] [Abstract][Full Text] [Related]
19. The Association of Carcinoembryonic Antigen and Cytokeratin-19 Fragments 21-1 Levels with One-Year Survival of Advanced Non-Small Cell Lung Carcinoma at Cipto Mangunkusumo Hospital: A Retrospective Cohort Study.
Rumende CM; Sugianto GCK; Rinaldi I; Muhadi M
Acta Med Indones; 2020 Apr; 52(2):140-146. PubMed ID: 32778628
[TBL] [Abstract][Full Text] [Related]
20. Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy.
Geiger K; Joerger M; Roessler M; Hettwer K; Ritter C; Simon K; Uhlig S; Holdenrieder S
Tumour Biol; 2024; 46(s1):S191-S206. PubMed ID: 38363625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]